Characterization of three abnormal factor IX variants (F

Journal of Clinical Investigation
75, 76-83
DOI: 10.1172/jci111700

Citation Report

#	Article	IF	Citations
1	The characterization of a panel of monoclonal antibodies to human coagulation factor IX. Thrombosis Research, 1985, 40, 863-867.	1.7	9
2	Heterogeneity of factor IX BM difference of cleavage sites by factor XIa and Ca2+in factor IX Kashihara, Factor IX Nagoya and Factor IX Niigata. Thrombosis Research, 1986, 42, 595-604.	1.7	11
3	Intrinsic versus extrinsic coagulation Kinetic considerations. Biochemical Journal, 1986, 239, 757-762.	3.7	29
4	Partial purification and characterization of extrinsic pathway inhibitor (the factor xa-dependent) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.7	41
5	Molecular defect in factor IXHilo, a hemophilia Bm variant: Arg----Gln at the carboxyterminal cleavage site of the activation peptide. Blood, 1989, 73, 718-721.	1.4	32
6	Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo. Blood, 1989, 73, 1540-1544.	1.4	26
7	Defective propeptide processing and abnormal activation underlie the molecular pathology of factor IX Troed-y-Rhiw. British Journal of Haematology, 1989, 72, 208-215.	2.5	20
8	Replacement of isoleucine-397 by threonine in the clotting proteinase factor IXa (Los Angeles and Long) Tj ETQq1 1 0.784314 rgBT /O Lack of correlation between the ox brain prothrombin time and the mutation site in the variant proteins. Biochemical Journal, 1990, 265, 219-225.	3.7	23
9	A sulfated rabbit endothelial cell glycoprotein that inhibits factor VIIa/tissue factor is functionally and immunologically identical to rabbit extrinsic pathway inhibitor (EPI). Thrombosis Research, 1991, 61, 515-527.	1.7	20
10	Identification of a new haemophilia BMcase produced by a mutation located at the carboxy terminal cleavage site of activation peptide. British Journal of Haematology, 1991, 78, 385-389.	2.5	6
11	Comparison of the behavior of normal factor IX and the factor IX BM variant hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources. American Journal of Hematology, 1993, 43, 177-182.	4.1	6
12	Mutations in the catalytic domain of factor IX that are related to the subclass hemophilia Bm. Biochemistry, 1993, 32, 6324-6329.	2.5	14
13	[6] Human factor IX and factor IXa. Methods in Enzymology, 1993, 222, 96-128.	1.0	44
14	Prothrombin time using thromboplastins of different origin in hemophilia BM patients. American Journal of Hematology, 1994, 47, 245-246.	4.1	0
15	Evidence Suggestive of Activation of the Intrinsic Pathway of Blood Coagulation After Injection of Factor Xa/Phospholipid Into Rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 133-139.	2.4	10
16	Anticoagulant repertoire of the hookworm Ancylostoma caninum.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 2149-2154.	7.1	251
17	Protease and EGF1 Domains of Factor IXa Play Distinct Roles in Binding to Factor VIIIa. Journal of Biological Chemistry, 1999, 274, 18477-18486.	3.4	71
18	Detailed characterization of an anti-factor IX monoclonal antibody that neutralizes the prolonged ox brain prothrombin time of hemophilia BM by synthetic peptides. Peptides, 2000, 21, 603-608.	2.4	4

#	Article	IF	Citations
19	Congenital Bleeding Disorders of the Vitamin Kâ€Dependent Clotting Factors. Vitamins and Hormones, 2008, 78, 281-374.	1.7	38
20	Blood clotting factor IX BM Nagoya. Journal of Biological Chemistry, 1989, 264, 21257-21265.	3.4	24
21	Experimental and theoretical evidence supporting the role of Gly363 in blood coagulation factor IXa (Gly193 in chymotrypsin) for proper activation of the proenzyme.. Journal of Biological Chemistry, 1990, 265, 2956-2961.	3.4	24
22	Structure and Function of Factor IX: Defects in Haemophilia B. Clinics in Haematology, 1985, 14, 359-383.	2.3	39
23	Molecular Biology of Hemophilia B. Thrombosis and Haemostasis, 1993, 70, 001-009.	3.4	64
24	Expression of tissue factor and factor VIIa/tissue factor inhibitor activity in endotoxin or phorbol ester stimulated U937 monocyte-like cells. Blood, 1988, 71, 259-262.	1.4	18
25	Genetic defect responsible for the dysfunctional protein: factor IXLong Beach. Blood, 1988, 72, 820-822.	1.4	24
26	F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes. Journal of Thrombosis and Haemostasis, 2022, 20, 69-81.	3.8	9
27	Molecular defect in factor IXBm Lake Elsinore. Substitution of Ala390 by Val in the catalytic domain.. Journal of Biological Chemistry, 1988, 263, 10545-10548.	3.4	22
28	Structure, function, and molecular defects of factor IX. Blood, 1986, 67, 565-572.	1.4	38
29	The Molecular Basis of FIX Deficiency in Hemophilia B. International Journal of Molecular Sciences, 2022, 23, 2762.	4.1	16